Drug updated on 12/11/2024
| Dosage Form | Capsules (oral: 100 mg, 200 mg, 300 mg) |
| Drug Class | Sympathomimetics |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of orthostatic dizziness and light-headedness or the feeling that you are about to black out in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Pharmacologic treatments, including droxidopa, midodrine, ivabradine, bisoprolol, fludrocortisone, desmopressin, propranolol, modafinil, methylphenidate, and melatonin, were effective in reducing postural orthostatic tachycardia syndrome (POTS) symptoms and improving orthostatic tolerance.
- Effectiveness outcomes across the drugs were comparable, with each showing positive impacts on reducing POTS symptoms and enhancing patients’ ability to tolerate orthostasis.
- There is no safety information available in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Northera (droxidopa) Prescribing Information. | 2019 | Lundbeck, Deerfield, IL |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Choices and Challenges With Drug Therapy in Postural Orthostatic Tachycardia Syndrome: A Systematic Review | 2023 | Cureus |